<DOC>
	<DOCNO>NCT00003901</DOCNO>
	<brief_summary>RATIONALE : Prognostic test early sign metastasis may help doctor detect metastasis early plan effective treatment . PURPOSE : Phase III trial study relationship early sign metastasis survival patient stage I , stage II , stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Prognostic Study Metastases Patients With Stage I , Stage II , Stage III Non-small Cell Lung Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine relationship three indicator occult metastasis ( cytological examination pleural lavage , immunohistochemistry ( IHC ) assay lymph node , IHC assay rib bone marrow ) survival patient resectable non-small cell lung cancer . - Determine relationship indicator conventional histology . - Model survival consider indicator patient attribute prime prognostic significance . - Determine relationship indicator site first recurrence patient . - Determine prevalence indicator patient . - Determine relationship indicator disease free survival patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Patient must â‰¥ 18 year old . 2 . Patient must ECOG/Zubrod status &lt; 3 . 3 . Patient must clinically resectable , NSCLC ( squamous cell , adenocarcinoma , large cell ) clinical Stage I , IIa , IIb IIIa , accord 1998 stag system American Joint Commission Cancer lung cancer . 4 . Patient must N1 N2 disease . NOTE : Patient must undergo mediastinoscopy preoperative study suggest N3 disease . 5 . Patient must pathologic diagnosis ( preoperative intraoperative ) NSCLC prior registration . 6 . Patient must anticipate thoracotomy intention curative resection primary NSCLC . NOTE : The preoperative assessment resectability , minimum , include CT scan chest upper abdomen , include adrenal gland , within 60 day prior registration . 7 . Patient must medically fit surgery . 8 . Patient must candidate complete resection carcinoma via pneumonectomy , bilobectomy , lobectomy , anatomic segmentectomy without sleeve resection . 9 . Patient patient 's legally acceptable representative must provide sign dated write informed consent prior registration studyrelated procedure . 10 . Patient must available followup . 11 . If patient survivor prior cancer , follow criterion must apply : 1 . Patient undergone potentially curative therapy prior malignancy , 2 . No evidence prior malignancy least 5 year evidence recurrence ( except effectively treat basal cell squamous carcinoma skin , carcinoma insitu cervix effectively treat surgery alone , lobular carcinoma insitu ipsilateral contralateral breast treat surgery alone ) , 3 . Patient deem treat physician low risk recurrence prior malignancy . 1 . Patient evidence pleural effusion physical assessment , lateral chest xray , chest CT scan . 2 . Patient ipsilateral thoracotomy thoracoscopy within past 5 year . 3 . Patient receive prior chemotherapy radiotherapy cancer . 4 . Patient consider poor surgical risk due nonmalignant systemic disease ( cardiovascular , renal , etc . ) would preclude treatment option . 5 . Patient surgeon plan perform wedge resection treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>